Drug · CHEMBL4650488
ETESEVIMAB
7 sourcespipelines-2026-09-18-0.3.1
Cite this record
ConductScience Library. ETESEVIMAB. Drugs and targets, record CHEMBL4650488. Release pipelines-2026-09-18-0.3.1, 18 Sept 2026. https://conductscience.org/library/drugs/CHEMBL4650488
On this page
Drug
Names and IDs as ChEMBL gives them, through Open Targets.
- Other names
- Anti-sars-cov-2 antibody js016, CB-6, CB6, JS-016, JS016, LY COV016, LY-3832479, LY-COV016, LY3832479, Ly3832479, NP-005, NP005
- ChEMBL
Targets0
The targets ChEMBL's mechanism records give for the drug, through Open Targets. A mechanism record says what the drug acts on, not how strongly.
None in this release.
Diseases1
The diseases Open Targets' clinical reports study the drug for, the most trial reports first. The stage is Open Targets', the highest any of its sources reports for the pair, and each row names the sources that report it.
| Disease | Open Targets' stage | Stage reported by | Reports | Of them trials | Its drugs |
|---|---|---|---|---|---|
| COVID-19 | Phase 3 | ClinicalTrials.gov | 14 | 13 | https://conductscience.org/library/drugs?q=MONDO_0100096 |
Source Open Targets
Trials19
Trials whose record names the drug by a name ChEMBL states, posted results first, then the largest. Open Targets read each trial's text to find its drugs.
| Trial | Title | Phase | Participants | Results first posted | Named as | Linked by | Source |
|---|---|---|---|---|---|---|---|
| NCT04790786 | UPMC OPTIMISE-C19 Trial, a COVID-19 Study | Phase 4 | 4,571 | 2023-06-15 | etesevimab | Its name | ClinicalTrials.gov |
| NCT04427501 | A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Participants With Mild to Moderate COVID-19 Illness | Phase 2/3 | 3,307 | 2022-03-07 | etesevimab | Its name | ClinicalTrials.gov |
| NCT04634409 | A Study of Immune System Proteins in Participants With Mild to Moderate COVID-19 Illness | Phase 2 | 1,755 | 2022-07-01 | etesevimab | Its name | ClinicalTrials.gov |
| NCT04602000 | A Phase 2/3 Study to Evaluate the Efficacy and Safety of CT-P59 in Patients With Mild to Moderate SARS-CoV-2 Infection | Phase 2/3 | 1,642 | 2022-07-20 | etesevimab | Its name | ClinicalTrials.gov |
| NCT04497987 | A Study of LY3819253 (LY-CoV555) and LY3832479 (LY-CoV016) in Preventing SARS-CoV-2 Infection and COVID-19 in Nursing Home Residents and Staff | Phase 3 | 1,180 | 2022-02-04 | etesevimab | Its name | ClinicalTrials.gov |
| NCT04913675 | Intramuscular and Intravenous VIR-7831 (Sotrovimab) for Mild/Moderate COVID-19. | Phase 3 | 1,065 | 2023-05-26 | etesevimab | Its name | ClinicalTrials.gov |
| NCT04441931 | A Study of LY3832479 (LY-CoV016) in Healthy Participants | Phase 1 | 26 | 2021-12-06 | LY3832479 | Its name | ClinicalTrials.gov |
| NCT04611789 | A Study of LY3832479 (LY-CoV016) in Healthy Participants 1 | Phase 1 | 18 | 2021-12-06 | LY3832479 | Its name | ClinicalTrials.gov |
| NCT05205759 | Non-inferiority Trial on Monoclonal Antibodies in COVID-19 | Phase 3 | 319 | etesevimab | Its name | ClinicalTrials.gov | |
| NCT04931238 | Efficacy and Safety of JS016 in Patients With SARS-CoV-2 Infection (COVID-19) | Phase 2 | 200 | JS016 | Its name | ClinicalTrials.gov |
1 to 10 of 19
See all 19 trialsComparisons in its trials4
Comparisons Trial comparisons calculated in the trials whose record names the drug, most participants first. A comparison in one of its trials does not always compare the drug, so read the two groups.
| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
CT-P59 40 mg/kg Group (Part 2) vs Placebo Group (Part 2): Proportion of Patients With Clinical Symptom Requiring Hospitalization, Oxygen Therapy, or Experiencing Mortality Due to SARS-CoV-2 Infection up to Day 28 in All Randomized Patients (Part 2) | 16 of 656 | 53 of 659 | 1,315 | NCT04602000 | Trial comparisons |
| 4200mg Bamlanivimab vs Placebo: deaths from any cause | 13 of 588 | 21 of 587 | 1,175 | NCT04497987 | Trial comparisons |
| 4200mg Bamlanivimab vs Placebo: serious adverse events | 39 of 588 | 30 of 587 | 1,175 | NCT04497987 | Trial comparisons |
CT-P59 40 mg/kg Group (Part 2) vs Placebo Group (Part 2): Proportion of Patients With Clinical Symptom Requiring Hospitalization, Oxygen Therapy, or Experiencing Mortality Due to SARS-CoV-2 Infection up to Day 28 in High-risk Patients (Part 2) | 14 of 446 | 48 of 434 | 880 | NCT04602000 | Trial comparisons |
Papers from its trials24
The papers the trials whose record names the drug list on ClinicalTrials.gov as their results (RESULT) or as drawn from them (DERIVED), results first, newest first.
| PMID | Listed as | Trials listing it | Source |
|---|---|---|---|
| 33215063 | RESULT | 1 | PubMed |
| 39230829 | DERIVED | 1 | PubMed |
| 38291279 | DERIVED | 1 | PubMed |
| 37577112 | DERIVED | 1 | PubMed |
| 37520411 | DERIVED | 1 | PubMed |
| 37329415 | DERIVED | 1 | PubMed |
| 36413383 | DERIVED | 1 | PubMed |
| 36043180 | DERIVED | 1 | PubMed |
| 35834252 | DERIVED | 1 | PubMed |
| 35713300 | DERIVED | 6 | PubMed |
1 to 10 of 24
See all 24 papers from its trialsTests in its trials0
The tests ConductCognition runs that the trials whose record names the drug name in their registered outcomes, as ScienceGraph matched them. ConductCognition's list names the tests it runs, not every test a trial used.
None in this release.
Data dates
The date of each source this release read.
Sources 7
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ConductCognition's list of its testsOur own data
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ConductCognition's list of its testsOur own data: ConductCognition's list of its tests, https://conductcognition.com
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this drug from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/drugs/v1/CHEMBL4650488
GET https://conductscience.org/api/drugs/v1/CHEMBL4650488/papers?page=2